The status of new anticoagulants Journal Articles

abstract

• SummaryCurrently available anticoagulants include heparin, low‐molecular weight heparin, fondaparinux and warfarin. Despite advances with low‐molecular weight heparin and fondaparinux, the currently available agents have limitations that have provided the impetus for the development of new drugs for prevention and treatment of both venous and arterial thromboembolism. Novel anticoagulants targeting specific steps in coagulation are in various stages of development. This paper reviews the pharmacology of these new agents and describes the results of clinical trials with new anticoagulants in more advanced stages of clinical testing.

authors

• Bates, Shannon M
• Weitz, Jeffrey

status

• published 

publication date

• July 2006

has subject area

• 1102 Cardiorespiratory Medicine and Haematology (FoR)
• Anticoagulants (MeSH)
• Blood Coagulation (MeSH)
• Blood Coagulation Factors (MeSH)
• Fibrinolytic Agents (MeSH)
• Forecasting (MeSH)
• Heparin, Low-Molecular-Weight (MeSH)
• Humans (MeSH)
• Immunology (Science Metrix)
• Randomized Controlled Trials as Topic (MeSH)
• Recombinant Proteins (MeSH)
• Thrombin (MeSH)
• Thromboembolism (MeSH)

published in

• British Journal of Haematology  Journal

keywords

• Anticoagulants
• Blood Coagulation
• Blood Coagulation Factors
• Fibrinolytic Agents
• Forecasting
• Heparin, Low-Molecular-Weight
• Humans
• Randomized Controlled Trials as Topic
• Recombinant Proteins
• Thrombin
• Thromboembolism

Digital Object Identifier (DOI)

• 10.1111/j.1365-2141.2006.06134.x

PubMed ID

• 16803562

start page

• 3

end page

• 19

volume

• 134

issue

• 1